Vermillion, Inc. (VRML)
| Market Cap | 400.75M |
| Revenue (ttm) | 4.96M |
| Net Income (ttm) | n/a |
| Shares Out | 97.38M |
| EPS (ttm) | -0.17 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | Jun 11, 2020 |
| Last Price | $4.00 |
| Previous Close | $4.00 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | 3.93 |
| Day's Range | 4.00 - 4.75 |
| Day's Volume | 743,319 |
| 52-Week Range | 0.35 - 5.78 |
News
AUSTIN, Texas, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced management will participate in the ...
Conference Call scheduled for today, August 13th at 4:30 p.m. ET Conference Call scheduled for today, August 13th at 4:30 p.m. ET
Conference Call scheduled for today, August 13th at 4:30 p.m. ET Conference Call scheduled for today, August 13th at 4:30 p.m. ET
AUSTIN, Texas, July 31, 2020 (GLOBE NEWSWIRE) -- Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced it will report financial results for...
AUSTIN, Texas, July 01, 2020 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (Nasdaq: AWH) (“ASPIRA”), a bioanalytical-based women’s health company focused on gynecologic disease, today annou...
Vermillion, Inc. (NASDAQ: VRML) shares were trading higher on Wednesday, after the company announced it completed validation of new pre-surgical test offerings with OVA1 plus, including corona...
AUSTIN, Texas, June 10, 2020 (GLOBE NEWSWIRE) -- Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, is excited to announce that its...
AUSTIN, Texas, June 09, 2020 (GLOBE NEWSWIRE) -- Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced that it is set ...
Vermillion's (VRML) CEO Valerie Palmieri on Q1 2020 Results - Earnings Call Transcript
Conference Call scheduled for today, May 14th at 4:30 p.m. ET Conference Call scheduled for today, May 14th at 4:30 p.m. ET
Vermillion, Inc. (VRML) CEO Valerie Palmieri on Q4 2019 Results - Earnings Call Transcript
Vermillion, Inc. (VRML) CEO Valerie Palmieri on Q3 2019 Results - Earnings Call Transcript
Vermillion's (VRML) CEO Valerie Palmieri on Q2 2019 Results - Earnings Call Transcript
Vermillion's (VRML) CEO Valerie Palmieri on Q1 2019 Results - Earnings Call Transcript
Vermillion, Inc. (VRML) CEO Valerie Palmieri on Q4 2018 Results - Earnings Call Transcript
About VRML
Vermillion, together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women in the United States. The company's diagnostic tests include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor; and Overa, a multivariate index assay second generation test to determine the malignancy of ovarian cancer in women. It also offers in-vitro diagnostic ... [Read more...]
| Industry Diagnostics & Research | IPO Date Sep 29, 2000 |
| CEO Valerie Barber Palmieri | Employees 52 |
| Stock Exchange NASDAQ | Ticker Symbol VRML |
Financial Performance
In 2019, Vermillion's revenue was $4.54 million, an increase of 48.64% compared to the previous year's $3.05 million. Losses were -$15.24 million, 34.0% more than in 2018.